Parkinson's Disease (PD) is a chronic, progressive neurodegenerative disorder characterized by motor and non-motor symptoms. A comprehensive understanding of its pathophysiology and clinical management is vital for healthcare professionals.
PD is primarily associated with the loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies. This neuronal loss leads to an imbalance in the direct and indirect pathways of the basal ganglia, resulting in the characteristic motor symptoms of PD. The pathogenesis of PD is multifactorial, involving genetic susceptibility, environmental factors, and aging.
The clinical presentation of PD includes both motor and non-motor symptoms. The cardinal motor symptoms are bradykinesia, rigidity, rest tremor, and postural instability. Non-motor symptoms may precede motor symptoms and include olfactory dysfunction, sleep disorders, mood disorders, and autonomic dysfunction.
Diagnosis of PD is mainly clinical, based on the presence of characteristic motor symptoms and response to dopaminergic therapy. Neuroimaging, such as DaTSCAN, can support the diagnosis in uncertain cases. It is also important to differentiate PD from other parkinsonian syndromes.
Management of PD is symptomatic and individualized, aiming to improve quality of life. Pharmacotherapy, including levodopa and dopamine agonists, is the mainstay of treatment. Non-pharmacological interventions, such as physiotherapy and occupational therapy, play a crucial role. Deep brain stimulation is an option for patients with advanced disease and motor complications.
Understanding the pathophysiology of PD is fundamental to its clinical management. Early recognition of symptoms, accurate diagnosis, and individualized management can significantly improve the quality of life of patients with PD. Continued research is required to further elucidate the pathogenesis and to develop disease-modifying therapies.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation